Cargando…

Toward Personalized Cell Therapies: Autologous Menstrual Blood Cells for Stroke

Cell therapy has been established as an important field of research with considerable progress in the last years. At the same time, the progressive aging of the population has highlighted the importance of discovering therapeutic alternatives for diseases of high incidence and disability, such as st...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodrigues, Maria Carolina O., Glover, Loren E., Weinbren, Nathan, Rizzi, Jessica A., Ishikawa, Hiroto, Shinozuka, Kazutaka, Tajiri, Naoki, Kaneko, Yuji, Sanberg, Paul R., Allickson, Julie G., Kuzmin-Nichols, Nicole, Garbuzova-Davis, Svitlana, Voltarelli, Julio Cesar, Cruz, Eduardo, Borlongan, Cesar V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3227246/
https://www.ncbi.nlm.nih.gov/pubmed/22162629
http://dx.doi.org/10.1155/2011/194720
_version_ 1782217696773931008
author Rodrigues, Maria Carolina O.
Glover, Loren E.
Weinbren, Nathan
Rizzi, Jessica A.
Ishikawa, Hiroto
Shinozuka, Kazutaka
Tajiri, Naoki
Kaneko, Yuji
Sanberg, Paul R.
Allickson, Julie G.
Kuzmin-Nichols, Nicole
Garbuzova-Davis, Svitlana
Voltarelli, Julio Cesar
Cruz, Eduardo
Borlongan, Cesar V.
author_facet Rodrigues, Maria Carolina O.
Glover, Loren E.
Weinbren, Nathan
Rizzi, Jessica A.
Ishikawa, Hiroto
Shinozuka, Kazutaka
Tajiri, Naoki
Kaneko, Yuji
Sanberg, Paul R.
Allickson, Julie G.
Kuzmin-Nichols, Nicole
Garbuzova-Davis, Svitlana
Voltarelli, Julio Cesar
Cruz, Eduardo
Borlongan, Cesar V.
author_sort Rodrigues, Maria Carolina O.
collection PubMed
description Cell therapy has been established as an important field of research with considerable progress in the last years. At the same time, the progressive aging of the population has highlighted the importance of discovering therapeutic alternatives for diseases of high incidence and disability, such as stroke. Menstrual blood is a recently discovered source of stem cells with potential relevance for the treatment of stroke. Migration to the infarct site, modulation of the inflammatory reaction, secretion of neurotrophic factors, and possible differentiation warrant these cells as therapeutic tools. We here propose the use of autologous menstrual blood cells in the restorative treatment of the subacute phase of stroke. We highlight the availability, proliferative capacity, pluripotency, and angiogenic features of these cells and explore their mechanistic pathways of repair. Practical aspects of clinical application of menstrual blood cells for stroke will be discussed, from cell harvesting and cryopreservation to administration to the patient.
format Online
Article
Text
id pubmed-3227246
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-32272462011-12-08 Toward Personalized Cell Therapies: Autologous Menstrual Blood Cells for Stroke Rodrigues, Maria Carolina O. Glover, Loren E. Weinbren, Nathan Rizzi, Jessica A. Ishikawa, Hiroto Shinozuka, Kazutaka Tajiri, Naoki Kaneko, Yuji Sanberg, Paul R. Allickson, Julie G. Kuzmin-Nichols, Nicole Garbuzova-Davis, Svitlana Voltarelli, Julio Cesar Cruz, Eduardo Borlongan, Cesar V. J Biomed Biotechnol Review Article Cell therapy has been established as an important field of research with considerable progress in the last years. At the same time, the progressive aging of the population has highlighted the importance of discovering therapeutic alternatives for diseases of high incidence and disability, such as stroke. Menstrual blood is a recently discovered source of stem cells with potential relevance for the treatment of stroke. Migration to the infarct site, modulation of the inflammatory reaction, secretion of neurotrophic factors, and possible differentiation warrant these cells as therapeutic tools. We here propose the use of autologous menstrual blood cells in the restorative treatment of the subacute phase of stroke. We highlight the availability, proliferative capacity, pluripotency, and angiogenic features of these cells and explore their mechanistic pathways of repair. Practical aspects of clinical application of menstrual blood cells for stroke will be discussed, from cell harvesting and cryopreservation to administration to the patient. Hindawi Publishing Corporation 2011 2011-11-20 /pmc/articles/PMC3227246/ /pubmed/22162629 http://dx.doi.org/10.1155/2011/194720 Text en Copyright © 2011 Maria Carolina O. Rodrigues et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Rodrigues, Maria Carolina O.
Glover, Loren E.
Weinbren, Nathan
Rizzi, Jessica A.
Ishikawa, Hiroto
Shinozuka, Kazutaka
Tajiri, Naoki
Kaneko, Yuji
Sanberg, Paul R.
Allickson, Julie G.
Kuzmin-Nichols, Nicole
Garbuzova-Davis, Svitlana
Voltarelli, Julio Cesar
Cruz, Eduardo
Borlongan, Cesar V.
Toward Personalized Cell Therapies: Autologous Menstrual Blood Cells for Stroke
title Toward Personalized Cell Therapies: Autologous Menstrual Blood Cells for Stroke
title_full Toward Personalized Cell Therapies: Autologous Menstrual Blood Cells for Stroke
title_fullStr Toward Personalized Cell Therapies: Autologous Menstrual Blood Cells for Stroke
title_full_unstemmed Toward Personalized Cell Therapies: Autologous Menstrual Blood Cells for Stroke
title_short Toward Personalized Cell Therapies: Autologous Menstrual Blood Cells for Stroke
title_sort toward personalized cell therapies: autologous menstrual blood cells for stroke
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3227246/
https://www.ncbi.nlm.nih.gov/pubmed/22162629
http://dx.doi.org/10.1155/2011/194720
work_keys_str_mv AT rodriguesmariacarolinao towardpersonalizedcelltherapiesautologousmenstrualbloodcellsforstroke
AT gloverlorene towardpersonalizedcelltherapiesautologousmenstrualbloodcellsforstroke
AT weinbrennathan towardpersonalizedcelltherapiesautologousmenstrualbloodcellsforstroke
AT rizzijessicaa towardpersonalizedcelltherapiesautologousmenstrualbloodcellsforstroke
AT ishikawahiroto towardpersonalizedcelltherapiesautologousmenstrualbloodcellsforstroke
AT shinozukakazutaka towardpersonalizedcelltherapiesautologousmenstrualbloodcellsforstroke
AT tajirinaoki towardpersonalizedcelltherapiesautologousmenstrualbloodcellsforstroke
AT kanekoyuji towardpersonalizedcelltherapiesautologousmenstrualbloodcellsforstroke
AT sanbergpaulr towardpersonalizedcelltherapiesautologousmenstrualbloodcellsforstroke
AT allicksonjulieg towardpersonalizedcelltherapiesautologousmenstrualbloodcellsforstroke
AT kuzminnicholsnicole towardpersonalizedcelltherapiesautologousmenstrualbloodcellsforstroke
AT garbuzovadavissvitlana towardpersonalizedcelltherapiesautologousmenstrualbloodcellsforstroke
AT voltarellijuliocesar towardpersonalizedcelltherapiesautologousmenstrualbloodcellsforstroke
AT cruzeduardo towardpersonalizedcelltherapiesautologousmenstrualbloodcellsforstroke
AT borlongancesarv towardpersonalizedcelltherapiesautologousmenstrualbloodcellsforstroke